Opaleye Management’s Ginkgo Bioworks DNA Stock Holding History

Opaleye Management’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-500,000	Closed	-$5.63M	–	46
2025 Q2	$5.63M	Sell	500,000 -695,000	-58%	-$5.38M	1.14%	22
2025 Q1	$6.81M	Sell	1,195,000 -5,000	-0.4%	-$50.9K	1.52%	13
2024 Q4	$11.8M	Buy	1,200,000 +379,798	+46%	+$3.26M	2.06%	11
2024 Q3	$6.68M	Buy	+820,202	New	+$8.22M	1.11%	19
2022 Q3	–	Sell	-20,375	Closed	-$1.94M	–	45
2022 Q2	$1.94M	Sell	20,375 -2,870	-12%	-$350K	0.87%	29
2022 Q1	$3.75M	Hold	23,245	–	–	1.16%	24
2021 Q4	$7.73M	Buy	+23,245	New	+$11M	1.64%	22

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Opaleye Management's DNA Position: Q3 2025 in Review

Opaleye Management sold out of Ginkgo Bioworks (DNA) in Q3 2025, closing a stake of 500,000 shares — an estimated $5.63M sold.

Opaleye Management first reported a position in DNA in Q4 2021 and held it in 7 quarters. The position peaked at $11.8M in Q4 2024. 173 funds tracked by Wall St. Rank hold DNA as of Q3 2025.

Opaleye Management reported no remaining Ginkgo Bioworks position as of Q3 2025 after selling out during the quarter.
Opaleye Management sold 500,000 Ginkgo Bioworks shares in Q3 2025, an estimated $5.63M.
Opaleye Management first reported a position in Ginkgo Bioworks in Q4 2021 and held it in 7 quarters.
Opaleye Management's Ginkgo Bioworks position peaked at $11.8M in Q4 2024.
173 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2025.

Based on Opaleye Management's 13F filing for Q3 2025, filed 14 Nov 2025.